Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel To Assess Excessive Sedation Linked To Lilly’s Zyprexa Depot Formulation

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA Psychopharmacologic Drugs Advisory Committee will vote Feb. 6 on the safety and efficacy of the long-acting atypical antipsychotic.

You may also be interested in...



FDA Panel Gives Nod To Long-Acting Form Of Lilly’s Schizophrenia Drug Zyprexa

With appropriate label warnings, the excessive sedation side effect should not preclude approval of the atypical antipsychotic’s depot formulation.

FDA Panel Gives Nod To Long-Acting Form Of Lilly’s Schizophrenia Drug Zyprexa

With appropriate label warnings, the excessive sedation side effect should not preclude approval of the atypical antipsychotic’s depot formulation.

Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.

Related Content

Topics

UsernamePublicRestriction

Register

PS067339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel